Therefore, in animal models that exhibit extensive lung damage and pulmonary oedema in addition to inflammation, thus mimicking the key features of ARDS (Matute‐Bello et al., 2008; Monahan, 2013), there is, to the best of our knowledge, no clear evidence of beneficial effects of IL‐6R or IL‐1R antagonists at the peak of the acute exudative phase of ALI (day 7), which is a critical time point for ARDS resolution (Matthay et al., 2019; Ware & Matthay, 2000). Here, IL1R1 is linked to acute respiratory distress syndrome.